Alvaro Grana-Gomez
Madrid, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Whole-exome sequencing identifies MDH2 as a new familial paraganglioma gene.
Journal: Journal of the National Cancer Institute
Published: March 14, 2015
Functional and in silico assessment of MAX variants of unknown significance.
Journal: Journal of molecular medicine (Berlin, Germany)
Published: January 23, 2015
Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas.
Journal: Human molecular genetics
Published: December 17, 2013
Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways.
Journal: Endocrine-related cancer
Published: May 11, 2013
Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis.
Journal: Human molecular genetics
Published: February 19, 2013
Hematologic β-tubulin VI isoform exhibits genetic variability that influences paclitaxel toxicity.
Journal: Cancer research
Published: July 19, 2012
MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 29, 2012
Differential gene expression of medullary thyroid carcinoma reveals specific markers associated with genetic conditions.
Journal: The American journal of pathology
Published: December 16, 2011
Showing 1-8 of 8
Last Updated: 09/26/2026